Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e209-15. doi: 10.1016/j.ijrobp.2012.11.039. Epub 2013 Jan 16.

PMID:
23332383
2.

Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Eur Urol. 2014 Jan;65(1):177-85. doi: 10.1016/j.eururo.2012.08.070. Epub 2012 Sep 7.

PMID:
22981136
3.

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.

Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.

4.

Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.

Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1411-6. doi: 10.1016/j.ijrobp.2011.04.067. Epub 2011 Jun 25.

PMID:
21708431
5.

Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.

Winkfield KM, Chen MH, Dosoretz DE, Salenius SA, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e345-50. doi: 10.1016/j.ijrobp.2011.02.022. Epub 2011 Apr 20.

PMID:
21514066
6.

Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):147-52. doi: 10.1016/j.ijrobp.2009.04.085. Epub 2009 Sep 8.

PMID:
19744800
7.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

8.

Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.

Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1158-67. doi: 10.1016/j.ijrobp.2016.03.004. Epub 2016 Mar 11.

PMID:
27209511
9.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

10.

Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.

Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV.

Cancer. 2010 Feb 15;116(4):837-42. doi: 10.1002/cncr.24750.

11.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066
12.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

PMID:
19858385
13.

Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.

Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL.

Brachytherapy. 2013 Sep-Oct;12(5):415-21. doi: 10.1016/j.brachy.2013.02.005. Epub 2013 May 4.

PMID:
23651926
14.

Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.

PMID:
26181182
15.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

17.

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.

BJU Int. 2012 Oct;110(8):1116-21. doi: 10.1111/j.1464-410X.2012.11012.x. Epub 2012 Apr 30.

18.

Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.

Kovtun KA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

Cancer. 2016 Dec 1;122(23):3608-3614. doi: 10.1002/cncr.30224. Epub 2016 Aug 4.

PMID:
27490845
19.

Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.

Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV.

Cancer. 2010 Jun 1;116(11):2590-5. doi: 10.1002/cncr.24974.

20.

Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

Brachytherapy. 2015 Nov-Dec;14(6):781-7. doi: 10.1016/j.brachy.2015.08.004. Epub 2015 Sep 9.

PMID:
26361718

Supplemental Content

Support Center